Insider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,227 Shares of Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,227 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $10.15, for a total value of $388,004.05. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Hallal also recently made the following trade(s):

• On Friday, June 6th, David Hallal sold 38,228 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.24, for a total value of $391,454.72.

iTeos Therapeutics Stock Down 1.3%

Shares of iTeos Therapeutics stock traded down $0.13 during trading on Monday, hitting $10.04. 1,104,582 shares of the company were exchanged, compared to its average volume of 661,405. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.13. The stock has a market capitalization of $384.27 million, a price-to-earnings ratio of -3.19 and a beta of 1.51. The firm has a 50 day moving average price of $7.38 and a 200 day moving average price of $7.47.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ITOS has been the topic of several research analyst reports. Raymond James set a $12.00 price target on iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Piper Sandler restated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $15.86.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new position in iTeos Therapeutics in the 1st quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in iTeos Therapeutics in the 4th quarter valued at $42,000. CWM LLC raised its holdings in iTeos Therapeutics by 428.7% in the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after acquiring an additional 6,936 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of iTeos Therapeutics during the 1st quarter worth $65,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.